OSI sues Teva, Mylan for Tarceva patent infringement

Another day, another patent infringement lawsuit. Melville, NY-based OSI Pharmaceuticals says its suing Teva Pharmaceutical Industries and Mylan for trying to market generic versions of the daily cancer med Tarceva. Unless a court overturns the patent, OSI says the lawsuits will keep the FDA from approving Teva and Mylan's ANDAs until May 18, 2012. "OSI plans to vigorously protect and enforce the intellectual property rights of Tarceva," the company said in a statement.

Tarceva, a daily treatment for pancreatic and lung cancer, is marketed in the U.S. by OSI and Genentech.

- check out the OSI release

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.